STAT+: A possible comeback for a failed sickle cell gene therapy

China hits the brakes on controversial trials, RevMed’s red-hot cancer drug launch, and more biotech news Adobe Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The news is newsing hard these days, no? China hits the brakes on controversial trials China’s fast, cheap route to human testing is getting considerably less speedy. New government restrictions and news of recent patient deaths have slowed investigator-initiated trials, or IITs, STAT’s Jason Mast reports. This is perhaps to the chagrin of U.S. biotechs eager to bypass lengthy development timelines. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Meghana Keshavan covers biotech and contributes to The Readout newsletter. General Assignment Reporter Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.